8-K: Shuttle Pharma Secures $2.5M in Private Placement

Shuttle Pharmaceuticals Holdings, Inc. announced the closing of a private placement offering, raising approximately $2.5 million through the sale of pre-funded common stock purchase warrants.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. (the Company) closed a private placement offering on November 4, 2025.
• The Company issued and sold pre-funded warrants to purchase up to 625,156 shares of common stock.
• Aggregate gross proceeds from the offering were approximately $2.5 million.
• The pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable.
• A beneficial ownership limitation of 4.99% (or 9.99% upon election) applies to the exercise of warrants.
• The Company agreed to file a registration statement for the resale of the common stock issuable upon exercise of the warrants within 15 days and have it declared effective within 45 days (or 75 days if reviewed by the SEC).
• WestPark Capital, Inc. acted as the exclusive placement agent, receiving a cash fee of 4% of the gross proceeds.
• The Company agreed to a 15-day lock-up period on further equity sales, with certain exceptions.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for the company's operations and marketing, which is a positive. However, it comes with dilution and standard fees, and the company is still in a stage requiring such financing, indicating ongoing operational needs.

Positives

• Successfully raised approximately $2.5 million in gross proceeds, providing capital for general corporate purposes, working capital, and up to $800,000 for marketing.
• The pre-funded warrants have a nominal exercise price of $0.001, indicating most of the capital was received upfront.
• The Company is committed to registering the underlying shares for resale, which facilitates liquidity for investors.

Negatives

• A 4% cash fee paid to the placement agent reduces net proceeds.
• The issuance of warrants and underlying shares will result in dilution for existing shareholders.
• The 15-day lock-up period on subsequent equity sales might limit immediate future financing flexibility, though it also provides some stability.

Risks

• The securities were not registered under the Securities Act of 1933, relying on an exemption, which imposes transfer restrictions until registered or eligible for Rule 144.
• Beneficial ownership limitations (4.99% or 9.99%) restrict the immediate exercise of all warrants by a single holder.
• Failure to timely deliver warrant shares upon exercise could lead to rescission rights for the holder or compensation for 'Buy-In' costs.
• The issuance of the securities may result in dilution of the outstanding shares of Common Stock, which could be substantial under certain market conditions.

Future Outlook

The Company plans to use the net proceeds from the offering for general corporate purposes, working capital, and up to $800,000 for marketing. It also commits to filing a registration statement for the resale of the underlying shares within 15 days and aims for effectiveness within 45-75 days.

Management Comments

• Christopher Cooper, Interim Chief Executive Officer, signed the Form 8-K on behalf of Shuttle Pharmaceuticals Holdings, Inc.

Industry Context

This capital raise provides Shuttle Pharmaceuticals with additional funding, which is common for biotechnology or pharmaceutical companies, especially those in development stages, to support ongoing operations, research, and marketing efforts. The use of pre-funded warrants and a private placement is a typical financing mechanism for smaller public companies to raise capital efficiently while managing immediate dilution and regulatory requirements.

Comparison to Industry Standards

• N/A The filing details a specific financing transaction and does not provide performance metrics or project results that can be directly compared to global industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new shares upon warrant exercise. The capital raise provides funding for company operations, which could support long-term value.
• Investors (Purchasers of Warrants): Gain the right to acquire common stock at a nominal exercise price, with potential for future gains if the stock price increases, subject to beneficial ownership limitations.
• Employees: Continued operations and potential growth supported by new capital could provide job security and opportunities.

Next Steps

• File a registration statement with the SEC for the resale of the shares underlying the pre-funded warrants on or before November 18, 2025.
• Have the registration statement declared effective by the SEC on or before December 18, 2025 (or February 1, 2026, if reviewed).
• Maintain the listing of Common Stock on its Trading Market and apply to list the newly issued shares and warrant shares.
• Continue to reserve sufficient shares of Common Stock for the exercise of the pre-funded warrants.

Key Dates

Recommendation

The capital raise provides necessary funding for Shuttle Pharmaceuticals' operations and marketing, which is a positive for the company's stability and ability to pursue its strategic objectives. However, the issuance of pre-funded warrants introduces dilution for existing shareholders. While the funding is crucial, the company's continued reliance on such financing suggests it is still in a development phase with ongoing capital needs. Without further details on specific project milestones, clinical trial progress, or revenue generation, a 'hold' recommendation is appropriate, acknowledging the improved financial runway while awaiting clearer indicators of future growth and profitability.

Keywords

Shuttle Pharmaceuticals, SHPH, Private Placement, Pre-Funded Warrants, Capital Raise, SEC Filing, 8-K, Equity Financing, Dilution, Securities Purchase Agreement, WestPark Capital